Drugs / Argipressin
Argipressin
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT07063680 | Apr 2026 → Jan 2029 expected | — | Centre Hospitalier Universitaire Dijon | Recruiting | No outcome recorded |
| Phase 41 trial · 1 missed | ||||||
| Phase 4 | NCT05293041 | Mar 2022 → Dec 2024 | inflammatory disease, metastasis from malignant tumor of colon | Kristina Svennerholm | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Argipressin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07063680 ↗ |
| Known as | Arg | “Arg” NCT05293041 ↗ |
| Known as | Arginine Vasopressin | “Efficacy of Early Argipressin (Arginine Vasopressin) in the Management of Intensive Care Patients With Norepinephrine-refractory Vasoplegic Shock: a Multicentric Randomized,...” NCT07063680 ↗ |